Sanofi takes wisdom of crowd in social media blitz

Social media may be a potential minefield for Big Pharma, but some companies are finding their way safely. One of them is Sanofi ($SNY), which recovered from a Facebook slap from a disgruntled patient to move into the online networking world in a big way, at least when it comes to diabetes. The French drugmaker, like several of its rivals, is counting on growth in the diabetes market to help fuel its own sales. One way Sanofi is trying to set itself apart from other makers of diabetes medications is by engaging with patients online. Article

Suggested Articles

Trialbee has added ex-Lundbeck CEO Ulf Wiinberg and former Bristol-Myers Squibb SVP Lars Birgerson to its board of directors.

Researchers have enrolled 2,000 people with metastatic breast cancer in 7 months using a social media-enabled, direct-to-patient model of recruiting.

Medisafe has started pitching an app and services to increase medication adherence and facilitate patient recruitment to biopharma companies.